Aptorum Group Limited (APM)

NASDAQ: APM · Real-Time Price · USD
1.740
-0.060 (-3.33%)
Oct 8, 2024, 1:49 PM EDT - Market open
-3.33%
Market Cap 9.52M
Revenue (ttm) 431,378
Net Income (ttm) -2.82M
Shares Out 5.47M
EPS (ttm) -0.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,322
Open 1.900
Previous Close 1.800
Day's Range 1.740 - 1.900
52-Week Range 1.350 - 17.490
Beta 1.27
Analysts n/a
Price Target n/a
Earnings Date Apr 30, 2024

About APM

Aptorum Group Limited, through its subsidiaries, operates as a clinical stage biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutic products for the treatment of oncology and infectious diseases. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; ALS-1 to tr... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 18, 2018
Employees 3
Stock Exchange NASDAQ
Ticker Symbol APM
Full Company Profile

Financial Performance

In 2023, Aptorum Group's revenue was $431,378, a decrease of -66.71% compared to the previous year's $1.30 million. Losses were -$2.82 million, -71.18% less than in 2022.

Financial Statements

News

Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “We”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, auto...

5 months ago - Business Wire

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company (“Aptorum”), and privately-held YOOV Group Holding Ltd. (“YOOV”) jointly announced t...

7 months ago - Business Wire

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncol...

10 months ago - Business Wire

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology,...

10 months ago - Business Wire

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology,...

11 months ago - Business Wire

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

NEW YORK--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announced that it has received an approval letter from the Na...

1 year ago - Business Wire

Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company focused on novel technologies including the t...

1 year ago - Business Wire

Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (the “Company”) (NASDAQ:APM, Euronext Paris:APM) announced today that following a comprehensive review of the trading...

1 year ago - Business Wire

Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity Deficiency

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicat...

1 year ago - Business Wire

Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group's Subsidiary Paths Innovations Limited

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Company”), today announced that its wholly owned subsidiary A...

1 year ago - Business Wire

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “We”), a clinical stage biopharmaceutical company dedicated to...

1 year ago - Business Wire

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Company”), today announced that it entered into a non-binding...

1 year ago - Business Wire

Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / March 17, 2023 / RedChip Companies will air new interviews with Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) and ASP Isotopes Inc. (Nasdaq:ASPI) on The RedChip Mon...

Other symbols: ASPI
1 year ago - Accesswire

Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announ...

1 year ago - Business Wire

Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announ...

1 year ago - Business Wire

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a clinical-stage biopharmaceutical company focused on the devel...

1 year ago - Business Wire

Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicat...

1 year ago - Business Wire

Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

1 year ago - Business Wire

Aptorum Group Announces 1-for-10 Reverse Stock Split

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

1 year ago - Business Wire

Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

1 year ago - Business Wire

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

1 year ago - Business Wire

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

1 year ago - Business Wire

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / November 25, 2022 / RedChip Companies will air a new interview Aptorum Group Limited (NASDAQ:APM)(Euronext Paris:APM), a clinical stage biopharmaceutical company dedicated t...

2 years ago - Accesswire